These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 20586986

  • 1. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea.
    Bae JY, Kim CH, Lee EK.
    Value Health; 2009; 12 Suppl 3():S70-3. PubMed ID: 20586986
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.
    Clin Drug Investig; 2009 Feb; 29(10):655-65. PubMed ID: 19715382
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP.
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [Abstract] [Full Text] [Related]

  • 6. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D, Tappenden P, Peters J, Kenjegalieva K.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [Abstract] [Full Text] [Related]

  • 7. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K, Mörk AC, Willers S, Lindgren B.
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [Abstract] [Full Text] [Related]

  • 9. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM, Lyseng-Williamson KA.
    Pharmacoeconomics; 2010 Mar; 28(3):231-54. PubMed ID: 20108995
    [Abstract] [Full Text] [Related]

  • 10. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of varenicline for smoking cessation.
    Keiding H.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P, Knight C, Boler A, Baker C.
    Pharmacoeconomics; 2008 Jun; 26(6):497-511. PubMed ID: 18489200
    [Abstract] [Full Text] [Related]

  • 13. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
    Vemer P, Rutten-van Mölken MP.
    Value Health; 2010 Jun; 13(2):230-41. PubMed ID: 19804435
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
    Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T.
    Addiction; 2011 Oct; 106(10):1819-26. PubMed ID: 21561499
    [Abstract] [Full Text] [Related]

  • 15. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective.
    Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K.
    Acta Clin Belg; 2012 Oct; 67(6):416-22. PubMed ID: 23340147
    [Abstract] [Full Text] [Related]

  • 16. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.
    Mahmoudi M, Coleman CI, Sobieraj DM.
    Int J Clin Pract; 2012 Feb; 66(2):171-82. PubMed ID: 22257042
    [Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K, Wilson K, Murphy D, Riesco JA.
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [Abstract] [Full Text] [Related]

  • 18. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY, Lim SS, Wallace AL, Vos T.
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [Abstract] [Full Text] [Related]

  • 19. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation.
    Jackson KC, Nahoopii R, Said Q, Dirani R, Brixner D.
    J Occup Environ Med; 2007 Apr; 49(4):453-60. PubMed ID: 17426529
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model.
    Knight C, Howard P, Baker CL, Marton JP.
    Value Health; 2010 Apr; 13(2):209-14. PubMed ID: 19912599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.